» Articles » PMID: 34650781

The Correlation Between Hemostatic Parameters and Mortality Rate in Patients with Non-small Cell Lung Cancer

Overview
Journal Hematol Rep
Publisher MDPI
Date 2021 Oct 15
PMID 34650781
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The increasing level of hemostatic parameters and tumor markers were associated with cancer progression and poor prognosis, particularly in NSCLC. The objective of this study is to determine whether there was a correlation between hemostatic parameters and mortality rate in patients with NSCLC. This was a prospective analytical study with a pretest-posttest design which included 41 patients with diagnosis of NSCLC. Plasma levels of PT, APTT, TT, D-dimer, and fibrinogen were measured before initiation of chemotherapy and remeasured after 4 cycles or 6 cycles of chemotherapy, based on the clinical condition of patients. Then, patients were followed up for 1 year to evaluate the mortality rate. The majority of subjects were male (85.4%) with adenocarcinoma (75.6%). There was no significant difference in mean between adenocarcinoma and squamous cell carcinoma (P>0.05). Most patients died after one month of follow up (61%). The parameters which could predict high mortality rate in NSCLC were prolonged PT and the increased of D-dimer with RR>1, although they had not significant in statistical analysis (P>0.05). There is no correlation between hemostatic parameters and mortality rate in patients with NSCLC.

Citing Articles

Prognostic Biomarkers of Systemic Inflammation in Non-Small Cell Lung Cancer: A Narrative Review of Challenges and Opportunities.

Stares M, Brown L, Abhi D, Phillips I Cancers (Basel). 2024; 16(8).

PMID: 38672590 PMC: 11048253. DOI: 10.3390/cancers16081508.


The prognostic role of coagulation markers in the progression and metastasis of laryngeal squamous cell carcinoma.

Huang Q, Chen J, Huang Y, Xiong Y, Zhou J, Zhang Y BMC Cancer. 2023; 23(1):901.

PMID: 37749514 PMC: 10519099. DOI: 10.1186/s12885-023-11381-5.


Hypercoagulability State Combined with Post-Treatment Hypofibrinolysis in Invasive Breast Cancer: A Seven-Year Follow-Up Evaluating Disease-Free and Overall Survival.

Wrzeszcz K, Rhone P, Kwiatkowska K, Ruszkowska-Ciastek B Life (Basel). 2023; 13(5).

PMID: 37240751 PMC: 10222121. DOI: 10.3390/life13051106.


Development and validation of a nomogram model for lung cancer based on radiomics artificial intelligence score and clinical blood test data.

Hu W, Zhang X, Saber A, Cai Q, Wei M, Wang M Front Oncol. 2023; 13:1132514.

PMID: 37064148 PMC: 10090418. DOI: 10.3389/fonc.2023.1132514.

References
1.
Kim D, Nam T, Choe K, Choy H . Personalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer. Cancer Res Treat. 2012; 44(2):74-84. PMC: 3394867. DOI: 10.4143/crt.2012.44.2.74. View

2.
Guo Q, Zhang B, Dong X, Xie Q, Guo E, Huang H . Elevated levels of plasma fibrinogen in patients with pancreatic cancer: possible role of a distant metastasis predictor. Pancreas. 2009; 38(3):e75-9. DOI: 10.1097/MPA.0b013e3181987d86. View

3.
Blom J, Osanto S, Rosendaal F . The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost. 2004; 2(10):1760-5. DOI: 10.1111/j.1538-7836.2004.00928.x. View

4.
Kroger K, Weiland D, Ose C, Neumann N, Weiss S, Hirsch C . Risk factors for venous thromboembolic events in cancer patients. Ann Oncol. 2005; 17(2):297-303. DOI: 10.1093/annonc/mdj068. View

5.
Tas F, Kilic L, Serilmez M, Keskin S, Sen F, Duranyildiz D . Clinical and prognostic significance of coagulation assays in lung cancer. Respir Med. 2012; 107(3):451-7. DOI: 10.1016/j.rmed.2012.11.007. View